Avacta Therapeutics has received FDA clearance for their FAP-Exd (AVA6103) program, a tumor-activated oncology delivery platform. The Phase 1 clinical trial will evaluate the safety and efficacy of FAP-Exd in patients with pancreatic, cervical, gastric, and small cell lung cancer. The trial will have two arms investigating different administration schedules, with preliminary data expected in the second half of 2026. This milestone marks a significant advancement for the pre|CISION® platform, with the potential to maximize efficacy while minimizing toxicities. Clinicians are excited about the potential of concentrating potent cancer therapies directly in tumors to improve patient outcomes.

Read more at GlobeNewswire: Avacta Announces U.S. Food and Drug Administration